Benzinga | Nov 29, 2021 07:03AM EST

Immunome Announces Submission Of An Investigational New Drug Application For IMM-BCP-01 For The Treatment Of COVID-19

- IMM-BCP-01 targets three non-overlapping regions on the Spike protein to provide broad coverage across CDC current and former variants of concern

- IMM-BCP-01 elicits multi-modal activity in pre-clinical testing including ACE2 and non-ACE2 dependent neutralization, as well as natural viral clearance mechanisms